Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new recommendations e-published in Catheterization and Cardiovascular Interventions by the Society for Cardiovascular Angiography and Interventions (SCAI)
Teleflex has announced that a newly published clinical study demonstrates that the accuracy of the Arrow VPS G4 vascular positioning system, with placements of peripherally inserted central catheters (PICCs), can eliminate the use of confirmatory chest X-rays
Two-year data from a prospective, multicentre study suggest that endovascular therapy with stenting may be considered the preferred first-line treatment option for aortoiliac lesions, irrespectively of TASC lesion category.
A study from Denmark finds that the most important factors to predict long-term competent veins after catheter-directed thrombolysis are symptom duration of less than two weeks and use of the pulse spray technique.
EmboCoh is a structured international web-based channel, designed so that physicians can enter their data on embolization procedures. It will enable collaborative registry-style data collection and analysis, particularly of uncommon embolization procedures, which would not be meaningfully possible from single-centre data due to the paucity of cases.
Biotronik has announced the start of enrolment and first Pulsar-18 self-expanding stent implantations in the investigator-initiated BIOFLEX PEACE study. Building on positive results for the 4F stent in the earlier 4EVER and PEACE trials, this new all-comers registry is designed to evaluate the Pulsar-18’s efficacy for interventions on femoropopliteal lesions in a larger group of patients in a real-world setting.
The Heart and Vascular Outcomes Research Institute (HVORI) is collaborating with a number of medical centres to launch the iRetrieve study aimed to improve the retrieval rate of inferior vena cava (IVC) filters. John E Rectenwald, associate professor of Surgery, University of Michigan is the principal investigator for iRetrieve study, and the clinical trial is currently underway.
Gynesonics has announced the first treatment of a patient in Cologne, Germany, using the company’s newly-designed VizAblate system. VizAblate is the only medical device to integrate ultrasound imaging with radiofrequency ablation in a single handheld device for the treatment of fibroids. The system is minimally invasive and is inserted through the cervix without any need for incisions.
The number of European Society of Radiology members has just passed the 60,000 mark, making it by far the largest community of radiologists in the world.
Findings from a review of the United States Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database reveal that complications occur with significantly higher frequency when retrievable inferior vena cava filters are placed than permanent filters. The study is in press in the Journal of Vascular and Interventional Radiology (JVIR).
AngioDynamics has announced obtaining 510(k) clearance for the Celerity tip location system from the US Food and Drug Administration (FDA). The Celerity system has been cleared by the FDA as an adjunct to aid in positioning Peripherally Inserted Central Catheters (PICCs) in adults by providing real time catheter tip location utilising the patient s cardiac electrical activity.
Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. The Emprint ablation system with Thermosphere technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumours.
Daisuke Kamoi, Nagoya Kyoritsu Hospital, Nagoya, Japan, reported on the first-in-man experience of angioscopy-guided chronic total occlusion techniques in peripheral arterial lesions at the EuroPCR congress (20–23 May, Paris, France). The system used in the study was the I-Light angioscopy system from iHeart Medical.
Biotronik has announced that the first patient has been enrolled in the investigator-initiated BIOLUX 4EVER trial. Given the positive results from each of the previous drug-eluting balloon and self-expanding stent trials, investigators were interested in exploring the combined use of the Pulsar-18 self-expanding stent and Passeo-18 Lux drug-eluting balloon to see if the outcome could be improved further. BIOLUX 4EVER will follow the study design of the previously completed, investigator-initiated 4EVER trial, which examined the efficacy of the Pulsar-18 self-expanding stent in the treatment of superficial femoral artery lesions, but this time adding the Passeo-18 Lux drug-eluting balloon to the treatment. The study will enrol 120 patients treated with both products, with the primary endpoint of primary patency at 12 months.
The US Food and Drug Administration (FDA) has approved the Fluency Plus Endovascular Stent Graft from Bard for the treatment of in-stent restenosis in the venous outflow of haemodialysis patients dialysing by either an arteriovenous fistula or access graft.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos